Akech Samuel, Nyamwaya Brian, Gachoki Jackline, Ogero Morris, Kigo Joyce, Maina Michuki, Mutua Edna, Ooko Ednah, Bejon Philip, Mwarumba Salim, Bahati Felix, Mvera Benedict, Musyimi Robert, Onsare Robert, Hutter Jack, Tanui Emmanuel, Wesangula Evelyn, Turner Paul, Dunachie Susanna, Lucey Olivia, McKnight Jacob
Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Open Res. 2022 Oct 12;7:256. doi: 10.12688/wellcomeopenres.18289.1. eCollection 2022.
Antimicrobial resistance (AMR) is a global threat and is thought to be acute in low-and middle-income country (LMIC) settings, including in Kenya, but there is limited unbiased surveillance that can provide reliable estimates of its burden. Current efforts to build capacity for microbiology testing in Kenya are unlikely to result in systematic routine microbiological testing in the near term. Therefore, there is little prospect for microbiological support to inform clinical diagnoses nor for indicating the burden of AMR and for guiding empirical choice of antibiotics. We aim to build on an existing collaboration, the Clinical Information Network (CIN), to pilot microbiological surveillance using a model where selected hospitals are linked to high quality microbiology research laboratories. Children admitted to paediatric wards of 12 participating hospitals will have a sample taken for blood culture at admission before antibiotics are started. Indication for blood culture will be a clinician's prescription of antibiotics. Samples will then be transported daily to the research laboratories for culture and antibiotic susceptibility testing and results relayed back to clinicians for patient management. The surveillance will take place for 6 months in each hospital. Separately, we shall conduct semi-structured interviews with frontline health workers to explore the feasibility and utility of this approach. We will also seek to understand how the availability of microbiology results might inform antibiotic stewardship, and as an interim step to the development of better national or regional laboratories linked to routine surveillance. If feasible, this approach is less costly and periodic surveillance can be used to track AMR trends and to broadly guide empirical antibiotic guidance meaning it is likely to be more sustainable than establishing functional microbiological facilities in each hospital in a LMIC setting.
抗菌药物耐药性(AMR)是一个全球性威胁,在包括肯尼亚在内的低收入和中等收入国家(LMIC)环境中被认为尤为严重,但能够提供其负担可靠估计的无偏倚监测却很有限。目前肯尼亚为加强微生物检测能力所做的努力近期不太可能导致系统的常规微生物检测。因此,微生物学支持对临床诊断提供信息、表明AMR负担以及指导抗生素经验性选择的前景渺茫。我们旨在基于现有的合作项目——临床信息网络(CIN),采用一种将选定医院与高质量微生物学研究实验室相连接的模式,开展微生物监测试点。入住12家参与医院儿科病房的儿童在开始使用抗生素之前,入院时将采集血培养样本。血培养的指征将是临床医生开具的抗生素处方。然后样本将每天送往研究实验室进行培养和抗生素敏感性检测,并将结果反馈给临床医生用于患者管理。每家医院的监测将持续6个月。另外,我们将对一线医护人员进行半结构化访谈,以探讨这种方法的可行性和实用性。我们还将试图了解微生物学检测结果的可获得性如何为抗生素管理提供信息,以及作为建立与常规监测相连接的更好的国家或地区实验室的过渡步骤。如果可行,这种方法成本较低,定期监测可用于跟踪AMR趋势并广泛指导经验性抗生素使用,这意味着它可能比在低收入和中等收入国家环境中的每家医院建立功能性微生物学设施更具可持续性。